These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21478119)

  • 1. The impact of new generation drug-eluting stent implantation on patients with chronic kidney disease and a single lesion in the proximal segment of the left anterior descending artery.
    Toutouzas K; Patsa C; Synetos A; Karanasos A; Karampelas J; Tsiamis E; Spanos A; Stefanadi E; Tousoulis D; Stefanadis C
    Hellenic J Cardiol; 2011; 52(2):103-10. PubMed ID: 21478119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary experience report: Drug-eluting stents versus coronary artery bypass surgery in patients with a single lesion in the proximal left anterior descending artery suffering from diabetes mellitus and chronic stable angina.
    Toutouzas K; Patsa C; Vaina S; Tsiamis E; Vavuranakis M; Stefanadi E; Spanos A; Iliopoulos D; Panagiotou M; Chlorogiannis I; Pattakos E; Stefanadis C
    Hellenic J Cardiol; 2008; 49(2):65-71. PubMed ID: 18459462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
    Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
    Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
    Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
    Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year follow-up of sirolimus-eluting stents for the treatment of proximal left anterior descending coronary artery stenosis.
    Valencia J; Berenguer A; Mainar V; Bordes P; Gómez S; Tello A; López-Aranda MA; Caturla J
    J Interv Cardiol; 2006 Apr; 19(2):126-34. PubMed ID: 16650240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late differences in outcomes of patients with stable angina and an isolated lesion in the proximal left anterior descending artery treated with new-generation drug-eluting stents.
    Toutouzas K; Anousakis-Vlachochristou N; Patsa C; Matsoukis IL; Drakopoulou M; Tsiamis E; Latsios G; Synetos A; Komatanou E; Spanos A; Petridou ET; Tousoulis D
    Int J Cardiol; 2015 Mar; 183():27-32. PubMed ID: 25662050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.
    Liistro F; Porto I; Angioli P; Grotti S; Ducci K; Falsini G; Bolognese L
    Am Heart J; 2013 Nov; 166(5):920-6. PubMed ID: 24176449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
    Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
    Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
    Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
    Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease.
    Wanitschek M; Pfisterer M; Hvelplund A; De Servi S; Bertel O; Jeger R; Rickenbacher P; Iversen A; Jensen JS; Galatius S; Kaiser C; Alber H;
    Int J Cardiol; 2013 Oct; 168(3):2381-8. PubMed ID: 23453439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results.
    López Mínguez JR; Nogales Asensio JM; Doncel Vecino LJ; Sandoval J; Romany S; Martínez Romero P; Fernández Díaz JA; Fernández Portales J; González Fernández R; Martínez Cáceres G; Merchán Herrera A; Alfonso Manterola F;
    EuroIntervention; 2014 May; 10(1):50-7. PubMed ID: 24832638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.
    Ota H; Mahmoudi M; Kitabata H; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2015 Mar; 16(2):84-9. PubMed ID: 25870152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis.
    Patra S; Chakraborty RN; Pande A; Banerjee S; Jena M; Mandal PC; De SK; Khan A; Das SS; Ghosh D; Nag R
    Cardiovasc Revasc Med; 2017; 18(3):160-164. PubMed ID: 28017259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unprotected left main stenting with a second-generation drug-eluting stent: one-year outcomes of the LEMAX Pilot study.
    Salvatella N; Morice MC; Darremont O; Tafflet M; Garot P; Leymarie JL; Chevalier B; Lefèvre T; Louvard Y; Boudou N; Dumonteil N; Carrié D
    EuroIntervention; 2011 Oct; 7(6):689-96. PubMed ID: 21986327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
    Hofma SH; Brouwer J; Velders MA; van't Hof AW; Smits PC; Queré M; de Vries CJ; van Boven AJ
    J Am Coll Cardiol; 2012 Jul; 60(5):381-7. PubMed ID: 22835668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.